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OBJECTIVES Given the importance of endothelial nitric oxide synthase (eNOS) in regulating endothelium-
dependent vasorelaxation, we investigated the effects of high-density lipoprotein in (HDL) on
eNOS protein abundance in cultured human vascular endothelial cells.
BACKGROUND Endothelial dysfunction, characterized by decreased nitric oxide production, is one of the
early features in the development of atherosclerosis. We have recently shown in vivo that
niacin therapy increases plasma HDL concentration and improves endothelium-dependent
vasorelaxation in patients with coronary artery disease.
METHODS Human vascular endothelial cells were cultured in the presence or absence of HDL or
apolipoprotein (apo)A-I. The eNOS protein abundance was assessed by immunoblotting, and
protein half-life was assessed by pulse-chase techniques. The eNOS messenger ribonucleic
acid (mRNA) abundance was measured using real-time quantitative polymerase chain
reaction.
RESULTS High density lipoprotein, or apoA-I alone, increased eNOS protein abundance by 3.5  0.7
and 2.7  0.5-fold, respectively (p  0.05 for both). However, neither HDL nor apoA-I
increased eNOS mRNA abundance. It was shown that HDL increased eNOS protein
half-life up to 3.3  0.2-fold (p  0.001). Both HDL and apoA-I activated mitogen-actived
protein-kinase and phosphatidylinositol 3-kinase (PI3K) Akt-pathways in human arterial
endothelial cells, and inhibition of either of these pathways by specific pharmacologic
inhibitors abolished the effect of HDL on eNOS.
CONCLUSIONS We demonstrate that HDL activates both extracellular signal-regulated kinase 1/2 (ERK1/2)
and Akt, resulting in enhanced eNOS protein stability and subsequent accumulation of
eNOS protein. This posttranslational regulation represents a previously unrecognized
mechanism for regulating eNOS. (J Am Coll Cardiol 2003;41:2288–97) © 2003 by the
American College of Cardiology Foundation
The association of low plasma high-density lipoprotein
(HDL) cholesterol and coronary artery disease (CAD) has
been well documented (1). We have recently shown that
patients with low HDL cholesterol have abnormal endo-
thelial function, despite having well-controlled low density
lipoprotein levels (2). Endothelial cell dysfunction, charac-
terized by decreased nitric oxide (NO) production, is one of
the early pathophysiologic events in the development of
atherosclerosis (3,4). Our recent study also demonstrated
that raising plasma HDL cholesterol in patients with CAD
improves endothelium-dependent vasorelaxation (2). We
showed further that in cultured endothelial cells, HDL can
increase the abundance of endothelial nitric oxide synthase
(eNOS) protein, the enzyme responsible for endothelium-
dependent vasorelaxation (2). The overall production of NO
by eNOS is regulated by two general mechanisms. The
activity of the enzyme is regulated by kinase-mediated
phosphorylation (5–7), by alteration of its intracellular
localization (8,9), and by alterations in eNOS protein
abundance. The abundance of eNOS protein is controlled
by alterations in gene transcription and/or messenger ribo-
nucleic acid (mRNA) stability (10–12). The current study
focused on understanding the mechanisms by which HDL
increases eNOS protein abundance.
MATERIALS AND METHODS
Lipoprotein isolation and apolipoprotein A-I. High
density lipoproteins were isolated from the plasma of
healthy volunteers by sequential ultracentifugation as previ-
ously described (2). Protease inhibitors and EDTA were
added to the plasma, which was maintained under aseptic
conditions at 4°C. The HDL was isolated at the density
of 1.09 to 1.21 g/ml after first removing lower-density
lipoproteins by separate ultracentrifugation, followed by an
additional wash run at 1.21 g/ml. Finally, HDL was
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dialyzed with several changes against phosphate-buffered
saline (PBS). The composition of the isolated HDL was
analyzed colorometrically using a Kone-specific selective
chemistry analyzer (Kone, Oy, Finland) and kits from
Boehringer and Wako Chemicals according to the manu-
facturer’s instructions. This contained, on average, 8.7
mg/ml cholesterol and 28.4 mg/ml protein. It also con-
tained 1.5 mmol/l triglyceride and 18.4 mmol/l phospho-
lipids. Purified human apoA-I was purchased from ICN
Pharmaceuticals, Costa Mesa, California. The stated con-
centrations of HDL used in experiments refer to the protein
content.
Cell culture. The EA.hy926 cells, immortalized human
aortic endothelial cells, the kind gift of Dr. Cora-Jean
Edgell (University of North Carolina), were cultured in
Dulbecco’s modified eagle medium (DMEM). Human
aortic endothelial cells (HAEC), purchased from Clontech
(Palo Alto, California) were grown in M199, each as
described (2). For each of the protocols described below, the
cells were grown to 80% confluence and maintained in
serum-and phenol red-free media for 36 h before treatment
as indicated for each experiment. Cells were then harvested
with triton-based lysis buffer.
Western blot analysis and antibodies. Endothelial cell
lysates (20 g of protein/sample) were separated by SDS–
PAGE and transferred onto nitrocellulose membranes,
which were probed with specific antibodies. Anti-eNOS
antibody was purchased from Transduction Laboratories
(Lexington, Kentucky) and anti-beta-actin was from
Sigma-Aldrich (St. Louis, Missouri). Antibodies against
total extracellular signal-regulated kinase 1/2 (ERK1/2),
phospho-ERK1/2 (pERK1/2), threonine307 phospho-Akt
(pAkt), and total Akt were from Cell Signaling (Beverly,
Massachusetts). The horseradish peroxidase-labeled sec-
ondary antibodies were purchased from Amersham-
Pharmacia (Piscataway, New Jersey). Detection of protein
bands was performed by enhanced chemiluminescence
(Amersham-Pharmacia) and the resulting films were sub-
jected to spot densitometry. For all experiments, quantifi-
cation of the abundance of the protein of interest was
normalized to the abundance of beta-actin, total ERK1/2,
or Akt.
Real-time quantitative polymerase chain reaction. Both
HAEC and EA.hy926 cells were incubated with HDL (50
g/ml), apoA-I (50 g/ml), 17-estradiol (10 nmol/l) or
vehicle control for 24 h. Total cellular RNA was isolated
using the RNeasy Mini kit (Qiagen, Valencia, California)
according to the manufacturer’s recommendations. The
cDNA was produced from 1 g of total cellular RNA by
reverse transcription using Taqman Reverse Transcription
reagents (Applied Biosystems) as instructed by the manu-
facturer. Negative controls were provided by performing an
identical reaction in the absence of reverse transcriptase or
template. Real-time quantitative polymerase chain reaction
(RT–PCR) was performed in the Perkin Elmer Biosystems
Gene Amp 7700 sequence detection system with SYBR
green PCR Master Mix (Applied Biosystems) according to
the manufacturer’s recommendations. Ten nanograms of
cDNA from RT reactions were used as a template, and the
reactions were carried out in the volume of 50 l in
triplicates. The sense and antisense primers for beta-actin
primers were 5AGCGGGAAATCGTGCGTGAC and
5TCCATGCCCAGGAAGGAAGG, and for eNOS
5CTTTGCTCGTGCCGTGGACA and 5GC-
CCTCGTGGACTTGCTGCT, respectively. Reactions
were first incubated at 50°C for 2 min to activate the urasil
N-glycosylase and then for 10 min at 95°C to inactivate the
urasil N-glycosylase and activate the Amplitaq Gold poly-
merase. Forty cycles of PCR consisting of denaturation at
95°C for 15 s and annealing and extension for 1 min at 60°C
were performed. To ensure the quantitative nature of the
results, serial dilutions of control cDNA were analyzed to
confirm that experiments were performed within the linear
range of the assay.
Data from RT–PCR were analyzed by standard method-
ology as previously described (13). The data were plotted as
fluorescence signal from each sample versus the cycle num-
ber. The threshold value was set at the midpoint of this
logarithmic fluorescence signal against cycle number plot.
The threshold cycle (CT) indicates the fractional cycle number
at which the amount of each amplified eNOS/beta-actin
mRNA reaches the fixed threshold. The fold-change in eNOS
mRNA abundance was determined by the equation:
Fold change 2CT, where CT (CT,eNOSCT,-actin)
control (CT,eNOSCT,-actin) target.
Quantification of eNOS mRNA half-life. The EA.hy926
cells were cultured as described above and incubated with 1
mol/l actinomycin D for 1 h. Either HDL (50 g/ml) or
PBS was then added to the cultures. Cells were harvested
after 0, 2.5, or 11 h, and total cellular RNA was isolated
using the RNeasy Mini kit (Qiagen). The RT–PCR analysis
of eNOS mRNA at each time-point was performed as
described above for the steady-state eNOS mRNA quanti-
fication. The fold-change in eNOS mRNA abundance at
each time-point was determined by the equation:
Fold change 2CT, where CT (CT,eNOS) target (CT,eNOS) 0 h.
Pulse-chase experiments. Endothelial cells were cultured
as described above followed by serum deprivation for an
additional 2 h in cysteine-, methionine-, and serum-free
Abbreviations and Acronyms
apo  apolipoprotein
CAD  coronary artery disease
eNOS  endothelial nitric oxide synthase
ERK1/2  extracellular signal-regulated kinase 1/2
HDL  high-density lipoprotein
PI3K  phosphatidylinositol 3-kinase
RT–PCR  real-time quantitative polymerase chain
reaction
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DMEM (Invitrogen, Carlsbad, California) and labeled for
1 h with a mixture of [35S]-methionine and [35S]-cysteine at
the specific radioactivity of 50 Ci/ml in the presence or
absence of HDL (50 g/ml). Cells were then rinsed five
times and incubated for up to 10 h with HDL (50 g/ml)
or vehicle, in medium containing 300 mg/l of nonradioac-
tive L-methionine and 630 mg/l of L-cysteine. Cells were
lysed and eNOS protein was immunoprecipitated using
monoclonal anti-eNOS antibody (Transduction Laborato-
ries). Immunopellets were subjected to SDS–PAGE, and
eNOS bands were detected using a phospho-imager. Par-
allel gels were blotted onto nitrocellulose membranes, and
membranes were probed for eNOS as described above to
ensure correct indentification of the eNOS protein band.
Immunocytochemistry. The EA.hy926 cells were incu-
bated with HDL (50 g/ml) and vehicle control for 0, 1, 3,
and 24 h. Cells were fixed with 3.7% paraformaldehyde in
PBS and then permeablized with 0.3% Triton X-100. Cells
were stained with eNOS monoclonal IgG1 (1:50 dilution),
and Caveolin-1 polyclonal (1:100) primary antibodies, pur-
chased from BD Transduction Laboratories, and secondary
antibodies FITC-conjugated donkey anti-mouse IgG (1:
50), and Cy3-conjugated donkey anti-rabbit IgG (1:500),
both obtained from Jackson ImmunoResearch, West Grove,
Pennsylvania. Single and merged images were prepared
using a Nikon OptiPhot-2 light microscope with fluores-
cent attachment and digital camera.
Signal transduction pathway experiments. The HAEC,
cultured as described above, were harvested after exposure to
HDL (50 g/ml), apoA-I (50 g/ml) or PBS-control for 0
to 24 h. The abundance of pERK1/2 or pAkt at each
time-point was quantified by immunoblotting and spot
densitometry. The density of the pERK1/2 or pAkt was
normalized against total ERK1/2 or total Akt values,
respectively.
In a subset of experiments, an inhibitor of MEK1-
mediated phosphorylation of ERK1/2, PD98059 (Calbio-
chem) or LY294002, an inhibitor of PI3K-mediated phos-
phorylation of Akt (Sigma-Aldrich), was added to the
cultures at concentrations ranging from 0 to 50 mol/l.
Cells were then pre-incubated for 30 min with the inhibi-
tors before stimulation with HDL or vehicle. Incubation
was continued for 0 to 24 h and the expressions of eNOS,
beta-actin, pERK1/2, total ERK1/2, pAkt, and total Akt
were analyzed by immunoblotting.
Statistical analysis. Pair-wise comparisons were performed
with a Student t test. Multiple comparisons were performed
using one-way analysis of variance (ANOVA) followed post
hoc by the Student-Newman-Keuls test. Data are expressed
as mean SEM unless otherwise indicated. A p 0.05 was
Figure 1. Both high-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) increase endothelial nitric oxide synthase (eNOS) protein abundance in
cultured human vascular endothelial cells. (A) Human vascular endothelial cells were treated with HDL at concentrations from 0 to 100 g/ml. After 24 h
of incubation, cells were lysed and the expressions of eNOS and -actin were analyzed by immunoblotting and spot densitometry. The HDL increased the
abundance of eNOS protein up to 3.5  0.7-fold at a concentration of 50 g/ml (p  0.05 vs. control). No further increase occurred at higher
concentrations of HDL (p  0.993 50 g/ml vs. 100 g/ml of HDL). (B) Purified human apolipoprotein A-I (apoA-I) was added to the HAEC cultures
at concentrations from 0 to 50 g/ml, and the effect of apoA-I on eNOS protein abundance was analyzed as described for HDL. The apoA-I increased
the amount of eNOS by 2.7  0.5-fold (p  0.004 vs. control, n  3). At lower doses, no significant difference existed between apoA-I–treated cells and
controls. Data presented in the upper panels are mean  SEM of three independent experiments. Lower panels show a representative experiment. *p 
0.05 vs. control; **p  0.01 vs. control.
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regarded as statistically significant. All statistical calcula-
tions were performed using Sigmastat version 2.03.
RESULTS
Both HDL and apoA-I increase eNOS protein abun-
dance in human vascular endothelial cells. Either
EA.hy926 cells or HAEC were cultured as described above
and incubated with HDL (0 to 100 g/ml). A small amount
of eNOS protein was detectable at baseline. The HDL
increased eNOS protein abundance up to 3.5  0.7-fold at
a concentration of 50 g/ml after 24 h of incubation (p 
0.05 vs. control, n  3; Fig. 1A). At higher concentrations
of HDL, no further increase occurred in eNOS abundance
(p  0.993 50 g/ml vs. 100 g/ml of HDL, n  3), and
no significant increase in eNOS was observed at earlier
time-points (data not shown). Similarly, at a dose of 50
g/ml, apoA-I increased eNOS protein abundance in
HAEC by 2.7  0.5-fold (p  0.004 vs. PBS control, n 
3; Fig. 1B). At doses of 5 and 10 g/ml of apoA-I, no
significant difference existed in eNOS abundance compared
to the control cells (p  0.26 and 0.45, respectively).
Neither HDL nor apoA-I increases eNOS mRNA levels
in human vascular endothelial cells. We next used RT–
PCR to determine whether HDL increases eNOS protein
abundance by increasing eNOS mRNA level. In preliminary
experiments, PCR reactions resulted in a single product of
Figure 2. Neither HDL nor apoA-I increases eNOS messenger ribonucleic acid (mRNA) abundance in human vascular endothelial cells. (A) Ethidium
bromide gel analysis of real-time quantitative polymerase chain reaction (RT–PCR) products demonstrating that only one band of the appropriate size was
visible after amplification of eNOS and -actin mRNA. Lanes 1 and 2  positive control; lane 3  no reverse transcriptase; lane 4  no template; lane
5  100 bp deoxyribonucleic acid-ladder. (B) A logarithmic amplification plot of standards for eNOS mRNA. The sets of plots represent data from
amplification of 5, 20, and 50 ng of standard cDNA plotted as fluorescence signal (Rn) versus cycle number. N  3 repetitive measurements of each
concentration are shown. (C) The effect of HDL, apoA-I, and 17--estradiol on eNOS mRNA abundance in human vascular endothelial cells. Cells were
treated with either HDL (50 g/ml), apoA-I (50 g/ml), 17--estradiol (10 nmol/l), or vehicle control for 24 h. Total cellular ribonucleic acid was
reverse-transcribed, and 10 ng of resulting complementary deoxyribonucleic acid was subjected to the real-time PCR analysis. Relative changes in eNOS
mRNA level were calculated as described in Materials and Methods. Neither HDL nor apoA-I increased eNOS mRNA abundance (p  0.093 and p 
0.145, respectively vs. control, n  4). Treatment with estradiol resulted in a 2.1  0.4-fold induction in eNOS mRNA level (p  0.001 vs. control, n
 4). Data are presented as mean  SEM. *p  0.001 vs. control. (D) The effect of HDL on eNOS mRNA stability. The eNOS mRNA abundance was
determined in actinomycin D–treated cells at various time-points after HDL (circles) or phosphate-buffered saline (PBS) (squares) treatment. The HDL
had no significant effect on eNOS mRNA half-life (n  3; p  0.5). Other abbreviations as in Figure 1.
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the expected size for both beta-actin and eNOS (Fig. 2A).
Serial dilutions of control cDNA were used to demonstrate
that the fold-induction in mRNA levels correlated linearly
with the amount of input cDNA (Fig. 2B). After validating
the assay, we then analyzed the effect of HDL (50 g/ml)
and apoA-I (50 g/ml) on eNOS mRNA abundance.
Surprisingly, neither HDL nor apoA-I significantly affected
eNOS mRNA levels (Fig. 2C). As expected, 17-beta-
estradiol significantly increased eNOS mRNA 2.1  0.06-
fold (p  0.001 vs. control, n  4; Fig. 2C). To determine
the effects of HDL on eNOS mRNA degradation, quanti-
tative RT–PCR analyses of eNOS mRNA abundance were
carried out in EA.hy926 cells pretreated with actinomycin D.
The half-life of eNOS mRNA was not significantly
changed in the presence of 50 g/ml HDL (2.9  0.6 h)
compared to PBS (3.6  0.5 h; Fig. 2D; n  3; p  0.5).
HDL increases eNOS protein stability. Pulse-chase ex-
periments were performed next to determine whether HDL
increases eNOS protein abundance by increasing the half-
life of eNOS protein. The HDL slowed the degradation of
eNOS protein by 3.3  0.2-fold, increasing its half-life
from 81  0.1 min to 270  24 min (p  0.001 vs. control,
n  3; Fig. 3). Immunocytochemical studies were next
performed to determine whether the HDL-induced in-
crease in eNOS protein stability was accompanied by
alterations in the intracellular localization of the protein. In
unstimulated cells, HDL co-localized with caveolin-1. Af-
ter 3 h of HDL treatment, eNOS translocated to a
predominantly peri-nuclear location, but then returned to
baseline by 24 h (Fig. 4). In contrast, PBS had no effect on
eNOS protein localization (Fig. 4).
Both HDL and apoA-I activate ERK1/2 and Akt in
human aortic endothelial cells. We hypothesized that
pathways regulating the enzymatic activity of eNOS might
also participate in regulating its abundance over longer time
periods. Therefore, as a first step in identifying the signaling
pathways that mediate the HDL-induced increase in eNOS
protein abundance, the effects of HDL on phosphorylation
of ERK1/2 and Akt were examined. Previous reports have
demonstrated that both MAP-kinase and Akt can regulate
eNOS enzymatic activity (5–7). The HDL increased the
amount of pERK1/2 in human arterial endothelial cells by
5.5  1.2-fold after 5 min of incubation (p  0.005 vs.
control, n  4; Fig. 5), and by 8.3  0.8-fold after 10 min
of incubation (p  0.001 vs. control, n  4; Fig. 5). The
activation was transient, because after 30 min of incubation
the HDL-induced increase in pERK1/2 abundance had
decreased to only 1.5  0.13-fold (n  4, p  0.02), and
after 3 h of incubation no significant difference existed
between HDL and control samples (p 0.6, n 4; Fig. 5).
Figure 3. HDL increases eNOS protein half-life in human vascular endothelial cells. (A) Autoradiograph showing immunoprecipitated eNOS protein from
a representative pulse-chase experiment after the indicated “chase periods.” (B) The averaged results of three pulse-chase experiments are shown. Open
circles represent cells treated with HDL (50 g/ml) and solid circles represent control cells. Incubation with HDL increased eNOS protein half-life from
81  0.1 to 270  24 min (p  0.001 vs. control, n  3). Data presented in B are mean  SEM; n  3 independent experiments. Abbreviations as in
Figure 1.
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Similarly, apoA-I increased the abundance of pERK1/2 in
human arterial endothelial cells by 2.3  0.3-fold after 5
min of incubation (p  0.001 vs. PBS, n  4) and 1.8 
0.2-fold following 10 min of incubation (p 0.002 vs. PBS,
n 4; Fig. 5). At later time-points, no significant difference
was seen in pERK1/2 abundance between apoA-I and
Figure 4. HDL causes transient migration of eNOS from the caveolae to a peri-nuclear distribution. The EA.hy926 cells were stained for both eNOS
(green) or caveolin (red) in serum-free medium (SFM) or after stimulation with HDL (50 g/ml) or PBS for 3 or 24 h. (Shown are representative images
from one of three independent experiments.) Abbreviations as in Figure 1.
Figure 5. HDL and apoA-I increase ERK1/2 phosphorylation in human arterial endothelial cells. The HAEC treated with either HDL (50 g/ml),
apoA-I (50 g/ml), or PBS were lysed at the indicated time-points and the amount of pERK1/2 and total ERK1/2 were measured by immunoblotting
and spot densitometry. The density of pERK1/2 bands was normalized against the corresponding total ERK1/2 band. The HDL increased the abundance of
pERK1/2 5.5  1.2-fold (p  0.005 vs. control) after 5 min of incubation and 8.3  0.8-fold (p  0.001 vs. control) after 10 min of incubation. The apoA-I
increased the abundance of pERK1/2 2.3  0.3-fold after 5 min of incubation (p  0.001 vs. control). Data shown are mean  SEM, n  4 independent
experiments. The lower panels depict a representative blot of each treatment. *p  0.005 vs. control; **p  0.001 vs. control. Abbreviations as in Figure 1.
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control samples. Also, HDL transiently increased the
amount of pAkt in human vascular endothelial cells by 2.2
 0.05-fold at 5 min (p  0.001 vs. control, n  3; Fig. 6).
The amounts of total ERK1/2 and Akt were not altered by
any of these stimuli over the time period examined.
Inhibition of either ERK1/2 or Akt activation inhibits
the HDL-induced increase in eNOS protein abundance.
The effect of pharmacologic inhibition of activation of
ERK1/2 and Akt on HDL-induced effects on eNOS
protein abundance was examined next. Incubation of cul-
tures with PD98059, a specific inhibitor of MEK1-
mediated ERK1/2 activation, dose-dependently inhibited
the transient HDL-induced phosphorylation of ERK1/2,
with complete inhibition of ERK1/2 phosphorylation
achieved at 50 mol/l (Fig. 7A). Pretreatement with 50
mol/l PD98059 also significantly blocked the effect of
HDL on eNOS protein abundance (p  0.029 between
HDL and HDL  50 mol/l PD98059, n  3).
Similarly, LY294002, an inhibitor of PI3K–mediated
activation of Akt, dose-dependently inhibited the transient
HDL-induced Akt phosphorylation (Fig. 7B), and this too
blocked the HDL-induced increase in eNOS protein abun-
dance (p  0.001 vs. control, n  3; Fig. 7B). Because
inhibition of either the PI3K/Akt or MAP-kinase pathways
alone was sufficient for inhibiting the effect of HDL on
eNOS protein abundance, the specificity of each of the
inhibitors for their respective pathways was examined. As
shown in Figure 7C, LY294002 did not inhibit HDL-
induced ERK1/2 phosphorylation, and PD98059 did not
inhibit HDL-induced Akt phosphorylation under these
experimental conditions.
DISCUSSION
The eNOS-dependent production of nitric oxide (NO) is
known to be regulated by two basic mechanisms. The better
studied of these involves alterations in the enzymatic activity
of the protein that occur rapidly in response to a variety of
stimuli, including HDL, which has been described to
rapidly activate eNOS in Chinese hamster ovary cells
(14,15). More recently it has also been clearly demonstrated
that eNOS protein expression can be both up- or down-
regulated by various stimuli, including estradiol (16), cyclic
strain (17), and HMG CoA reductase inhibitors (12).
According to current knowledge, each of these stimuli
increases eNOS protein abundance by increasing eNOS
mRNA levels, either by upregulating gene transcription or
by stabilizing mRNA (reviewed in Govers and Rabelink
[18]). In the current study, we demonstrate that HDL and
apoA-I also increase the amount of eNOS protein in
cultured human vascular endothelial cells. The different
dose-responses observed between HDL and apoA-I suggest
Figure 6. HDL increases Akt phosphorylation in human vascular endothelial cells. Cells were treated with HDL or PBS, lysed at the indicated time-points,
and the amount of pAkt and total Akt was measured by immunoblotting and spot densitometry. The density of the pAkt band was normalized against total
Akt. After 5 min of incubation, HDL increased the amount of pAkt in human vascular endothelial cells by 2.2  0.05-fold (p  0.001 vs. control). Data
are shown as mean  SEM, n  3 independent experiments. Lower panels depict a representative blot of each treatment. *p  0.001 vs. control.
Abbreviations as in Figure 1.
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that other components of the HDL particle may also
contribute to the observed response. Surprisingly, however,
HDL had no significant effect on eNOS mRNA levels or
half-life. Rather, HDL increased the half-life of eNOS
protein, apparently by decreasing degradation of the pro-
tein. Moreover, HDL treatment caused eNOS to tran-
siently adopt a peri-nuclear distribution, though the signif-
icance of this in terms of its effect on eNOS half-life
remains unclear. Taken together, these data support that,
unlike other stimuli known to upregulate eNOS protein
abundance, HDL increases eNOS protein abundance via a
posttranslational mechanism.
We next sought to identify signaling pathways that
contribute to HDL’s effect on eNOS protein abundance.
We hypothesized that the same pathways that rapidly
increase the enzymatic activity of eNOS might also initiate
the events necessary to lead to longer-term accumulation of
eNOS protein. Therefore, we examined whether HDL
alters the activity of two kinase-dependent signaling path-
ways that have previously been shown to regulate eNOS
activity, and we also sought to determine whether inhibition
of these pathways blocks HDL-mediated effects on eNOS
protein abundance. The current findings are consistent with
previous reports demonstrating that HDL, at physiologi-
cally relevant concentrations, transiently enhances phos-
phorylation of both MAP-kinase and Akt on sites previ-
Figure 7. Both PD98059 and LY294002 abolish the HDL-induced increase in eNOS protein abundance. (A) HDL increased the abundance of eNOS
by 3.6  0.53-fold (p  0.006 vs. PBS), and 50 mol/l PD98059 significantly inhibited this increase (p  0.029 vs. HDL). (B) HDL increased eNOS
protein abundance by 3.5  0.17-fold (p  0.001 vs. PBS), and LY294002 inhibited this increase dose-dependently and significantly at concentrations of
10 and 50 mol/l (p  0.001 vs. HDL, n  3). Data presented are mean  SEM, n  3 independent experiments. Lower panels depict a representative
blot. (C) Cells preincubated for 30 min in either PD98059 or LY294002 were stimulated with HDL for 5 min. Cells were lysed and the amount of
pERK1/2 and pAkt was then analyzed by Western blotting. The LY294002 did not inhibit HDL-induced ERK1/2 activation. Similarly, PD98059 did
not inhibit HDL-induced Akt activation. A representative blot of n  3 is shown. *p  0.01 vs. control; **p  0.001 vs. HDL; †p  0.001 vs. PBS; ‡p 
0.001 vs. HDL. Abbreviations as in Figure 1.
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ously shown to correlate with enhanced kinase activity of
each protein. Furthermore, pharmacologic inhibition of
HDL-mediated activation of either of these pathways alone
completely blocked HDL-induced increases in eNOS pro-
tein abundance. As shown in Figure 8, this suggests two
hypotheses: 1) that MAP-kinase and Akt are arranged
serially in the pathway that regulates eNOS protein stability,
such that inhibition of either kinase blocks this effect, or 2)
that MAP-kinase and Akt act via parallel pathways, but
activation of both pathways is required to enhance the
stability of eNOS. The observation that each of the kinase
inhibitors used in these studies results in inhibition of only
the anticipated pathway (Fig. 7C) indicates that the parallel
pathway model is more likely to be true. Though these
findings clearly implicate HDL-mediated activation of
MAP-kinase and Akt in the effect of HDL on eNOS
protein abundance, further investigation will be required to
determine the downstream effects of kinase cascade activa-
tion, which subsequently alters eNOS protein stability.
Study limitations. Several limitations of the current find-
ings deserve mention. First, we did not directly measure
enzymatic activity of the kinases of interest. However, the
phospho-forms identified by this technique have previously
been shown to correlate with enzyme activation (19,20).
Second, the data presented demonstrate that inhibition of
the HDL-induced rapid, transient increase in kinase phos-
phorylation also blocked HDL’s effect on eNOS protein
abundance, but they do not elucidate the downstream effects
that mediate this. A number of mechanisms can be envi-
sioned by which these early transient effects could lead to
delayed, longer-term effects. The kinases could directly alter
eNOS protein phosphorylation, which in turn alters inter-
actions with other proteins that regulate its degradation.
Both MAP-kinase and Akt have previously been shown to
alter the activity of transcription factors, and this could lead
to altered levels of a protein that then regulates eNOS
protein degradation. Clearly distinguishing between these
possibilities will require extensive additional experimenta-
tion. Finally, we did not directly investigate effects of HDL
on eNOS gene transcription.
Conclusions. In conclusion, we have demonstrated that
HDL activates both ERK1/2 and Akt, resulting, by an
unknown mechanism, in enhanced eNOS protein stability
and subsequent accumulation of eNOS protein. This post-
translational regulation represents a previously unrecognized
mechanism for regulating eNOS expression in the endothe-
lium. Taken together with our previous observation that
raising HDL in patients with CAD enhances endothelium-
dependent vasorelaxation (2), the current findings further
support an important role of HDL in regulating vascular
function.
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